LDK-378, ALK inhibitor CAS NO.1032900-25-6

All our products are in stock at our US office. Get fastest quotation, please visit www.activebiochem.com, thanks.

LDK-378 is the second generation of ALK inhibitor which shows substantial clinical activity in patients with ALK-positive non-small cell lung cancer (NSCLC), with an overall response rate of 81% in patients previously treated with the US FDA approved ALK inhibitor crizotinib (PF-02341066).

LDK-378 targets ALK, a key gene implicated in the development of some lung cancers, lymphomas, and childhood neuroblastomas. Approximately 6-8% of all NSCLCs are ALK-positive; these cancers are more likely to affect nonsmokers and younger individuals. LDK378 is a selective ALK inhibitor that has demonstrated enhanced potency over crizotinib and noteworthy antitumor activity in preclinical models, including in crizotinib-resistant tumors.